Status:
COMPLETED
Effect of Midodrine on HVPG in Advanced Chronic Liver Disease
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Chronic Liver Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
* Primary objective: HVPG response after administration of midodrine as defined by decrease in HVPG by \> 20 % from baseline or to less than equals to 12 mmHg. * Secondary objectives: Change in HVPG, ...
Eligibility Criteria
Inclusion
- \- i) CLD with grade III ascites with Na \< 130 / Systolic BP \< 90 / type 2 HRS(n=30 ) ii) ACLF (APASL criteria) with Na \< 130 / Systolic BP \< 90 / AKI (n=30)
Exclusion
- age \< 18 and \> 75,
- Pregnancy,
- Splanchnic venous thrombosis,
- Hepatocellular Carcinoma,
- Hepaticencephalopathy,
- Significant cardiopulmonary disease,
- Uncontrolled diabetes,
- Hypertension,
- Intrinsic renal disease,
- Peripheral vascular disease.
Key Trial Info
Start Date :
July 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04455464
Start Date
July 11 2020
End Date
December 13 2021
Last Update
December 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070